Evidence map›Paper›PMID 42020397›Full record

ArticleCell death & disease2026

SPP1

Yao Liang, Yuli Zheng, Zhimou Cai, Zhangrui Shi, Maoqia Shen, Ruixin Yu, Fang Wang, Xiaolong Cao, Rui Xu

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yao Liang *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yuli Zheng *Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zhimou Cai *Department of Otolaryngology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Zhangrui ShiDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Maoqia ShenDepartment of Anesthesiology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Ruixin YuDepartment of Dermatology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Fang WangDermatology Hospital, Southern Medical University, Guangzhou, China.
Xiaolong CaoDepartment of Anesthesiology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. atps@smu.edu.cn.ORCID http://orcid.org/0000-0001-8124-7491
Rui XuDermatology Hospital, Southern Medical University, Guangzhou, China. xurui25@alumni.sysu.edu.cn.ORCID http://orcid.org/0000-0003-0951-9354

Funding

China Postdoctoral Science Foundation 2024M753777
6 · The paper itself

Abstract

Melanoma is a highly aggressive skin cancer with biologically distinct subtypes. Acral melanoma (AM), a rare but particularly aggressive form, often presents with lymph node (LN) metastasis at diagnosis. Despite its clinical severity, the mechanisms underlying its metastatic behavior remain unclear. Emerging studies suggest the tumor microenvironment as a key driver of metastatic niche formation, but its specific role in AM progression is not well characterized. To investigate the role of the tumor microenvironment in AM progression, we performed single-cell RNA sequencing (scRNA-seq) on tumor tissues and matched adjacent normal samples from treatment-naïve AM patients, comparing cases with (LN

Indexed as

MacrophagesMelanomaOsteopontinSkin NeoplasmsTumor MicroenvironmentAnimalsCalgranulin ACell Line, TumorFemaleHumansLymphatic MetastasisMaleMiceSignal TransductionCalgranulin AOsteopontin

Identifiers

PMID42020397
PMCPMC13230793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.